Infinity I-China creates six new JV private equity funds

Infinity I-China, the world leader in Chinese international RMB funds, announced today the creation of six new joint venture (JV) private equity funds throughout China purposed to support the growth of local Chinese businesses through the influx of proven technology and know-how. The new funds are the third step in Infinity’s ten-year plan for the region, following its 2004 establishment of the first RMB fund in China and its 2008 cross-board fund. Step four will be announced later this year. Clal Industries from IDB Group, led by Infinity co-chairman Avi Fischer, is a strategic and ongoing supporter of these efforts.

“The quality of our deal flow alongside Infinity’s ability to add value has increased dramatically since our teams have spread out across the country”

“Since 2003, Infinity has been actively creating mutually beneficial relationships which combine the ingenuity and expertise of advanced and proven technology companies with the rapidly growing market in China and the business acumen of the Chinese people. Infinity chose to partner with Beijing, Suzhou, Harbin, Shijiazhuang, Changzhou, Ningbo and Tianjin, mainly because of the progressiveness, open-minded thinking and quality of leadership in these metropolises. It is the people that are compelling and on which we place the greatest value. Our ongoing relationship with Suzhou is a good example. The JV fund in Suzhou marks the third cooperation between Infinity and the fine leadership of this beautiful city. We look forward to long-term and exciting relations with our new friends across the country,” said Infinity I-China managing partner Mr. Amir Gal-Or.

Under the terms of the various agreements, the funds will range in size from 200 million RMB to a goal of 500 million RMB.

“The quality of our deal flow alongside Infinity’s ability to add value has increased dramatically since our teams have spread out across the country,” added Gal-Or.

Source:

Infinity I-China

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How Fluidics is Powering Modern Healthcare and Medical Device Innovation